Carcinoid TumorNCT07317726
Recent Trends in Stage Migration of Gastrointestnial Carcinoid Tumors Over Two Decades: a Retrospective SEER-based Analysis 2000-2022
An observational study of Carcinoid Tumor and SEER Database Analysis, run by Suez Canal University.
Trial summary
Stage migration occurs when patients sound to have better survival or increased incidence rates at the early stage at diagnosis due to early detection of the disease. As carcinoid tumors are rare and there are no data supporting stage migration, the aim of this study was to perform comprehensive trends analysis in… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Carcinoid Tumor, SEER Database Analysis, Stage
- How many people
- 93,481 participants
- Where
- No sites listed yet
- Study dates
- 1 Dec 2000to 30 Dec 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: the investigators analyzed the data from cancer registries participating in Surveillance, Epidemiology, and End Results (SEER) software for patients diagnosed with primary GI carcinoid tumors from 2000-2022 using a rate session to calculate the percent change and annual percent change in addition to incidence rates.
Who may be able to join
- patients with gastrointestinal carcinoid tumors
Who cannot join
- patients with unknown age data
About this study
Stage migration occurs when patients sound to have better survival or increased incidence rates at the early stage at diagnosis due to early detection of the disease. As carcinoid tumors are rare and there are no data supporting stage migration, the aim of this study was to perform comprehensive trends analysis in addition to survival analysis over two decades.
- Conditions
- Carcinoid Tumor, SEER Database Analysis, Stage
- Medical subject headings
- Carcinoid Tumor
What is being measured
The primary outcome is the main question the study is designed to answer.
The percent change and annual percent change for gastrointestinal carcinoids
Measured: 2000-2022
the percent change and annual percent change for gastrointestinal carcinoids across different stage distribution at diagnosis (localized, regional, distant, unknown)
Measured: 2000-2022
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jan 2026
- Study start1 Dec 2000
- Primary completion30 Dec 2022
- Study completion30 Dec 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Carcinoid TumorStudies of the same condition, open and under way.
- More trials run by Suez Canal UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 93,481 participants (actual)
Sponsor and investigators
- Lead sponsor
- Suez Canal University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, asmaa salama ibrahim, Suez Canal University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07317726
- Sponsor's protocol ID
- A278
- Status last verified
- Dec 2025
- First submitted
- 19 Dec 2025
- Last updated
- 5 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 5 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Recent Trends in Stage Migration of Gastrointestnial Carcinoid Tumors Over Two Decades: a Retrospective SEER-based Analysis 2000-2022
- ClinicalTrials.gov ID
- NCT07317726
- Acronym / sponsor ID
- A278
- Conditions
- Carcinoid Tumor, SEER Database Analysis, Stage
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 93,481 participants (actual)
- Lead sponsor
- Suez Canal UniversityUniversity, hospital or other
- Study start
- 1 Dec 2000 (actual)
- Primary completion
- 30 Dec 2022 (actual)
- Study completion
- 30 Dec 2022 (actual)
- First posted
- 5 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Stage migration occurs when patients sound to have better survival or increased incidence rates at the early stage at diagnosis due to early detection of the disease. As carcinoid tumors are rare and there are no data supporting stage migration, the aim of this study was to perform comprehensive trends analysis in addition to survival analysis over two decades.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- the investigators analyzed the data from cancer registries participating in Surveillance, Epidemiology, and End Results (SEER) software for patients diagnosed with primary GI carcinoid tumors from 2000-2022 using a rate session to calculate the percent change and annual percent change in addition to incidence rates.
Key inclusion criteria (1 listed)
- patients with gastrointestinal carcinoid tumors
Key exclusion criteria (1 listed)
- patients with unknown age data
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The percent change and annual percent change for gastrointestinal carcinoids
Time frame: 2000-2022
the percent change and annual percent change for gastrointestinal carcinoids across different stage distribution at diagnosis (localized, regional, distant, unknown)
Time frame: 2000-2022
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jan 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Carcinoid Tumor
RecruitingPhase 3
Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms
Neuroendocrine Neoplasm, Gastroenteropancreatic Neuroendocrine Neoplasm
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
RecruitingObservational study
Natural History of Familial Carcinoid Tumor
Carcinoid
RecruitingObservational study
Biomarkers in Patients With Respiratory Tract Dysplasia or Lung Cancer, Head and Neck Cancer, or Aerodigestive Tract Cancer and in Normal Volunteers
Esophageal Cancer, Head and Neck Cancer
RecruitingPhase 1
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Carcinoid Tumor and SEER Database Analysis, run by Suez Canal University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The percent change and annual percent change for gastrointestinal carcinoids (time frame: 2000-2022). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jan 2026.